MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

Year of Conference: 2011

Pages: 453-454

ISSN: 0006-4971

Publisher: American Society of Hematology

Library holdings: Search Newcastle University Library for this item

ISBN: 15280020

ePrints